AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
- More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016
- 自2016年設立以來,超過400名美國本科和研究生受益於艾伯維免疫學獎學金。
NORTH CHICAGO, Ill., Aug. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic, inflammatory diseases as they pursue higher education.
伊利諾伊州北芝加哥,2024年8月27日 /PRNewswire/ -- 艾伯維公司(紐交所:ABBV)今天宣佈2024-2025學年艾伯維免疫學獎學金獲獎者名單,旨在支持患有慢性炎症性疾病的學生追求更高的教育。
Experience the interactive Multimedia News Release here:
在此體驗互動多媒體新聞稿:
Due to the constraints of living with chronic illness, research finds that young adults with childhood-onset chronic illness have statistically lower rates of high school and college graduation.1 To honor the determination of these students, the AbbVie Immunology Scholarship strives to ease the financial burden and empower students to achieve their personal and academic aspirations.
由於患有慢性疾病的限制,研究發現兒童時期患有慢性疾病的年輕成年人的高中和大學畢業率統計上較低。爲了嘉獎這些學生的決心,艾伯維免疫學獎學金致力於減輕財務負擔,賦予學生實現個人和學術抱負的能力。
"AbbVie is deeply committed to caring for the whole patient in immunology," said Jérôme Bouyer, senior vice president and president of Immunology at AbbVie, "We are honored to support students as they pursue their academic journeys and strive toward a life beyond the constraints of their immune-mediated conditions."
艾伯維公司免疫學高級副總裁兼免疫學總裁Jérôme Bouyer表示:「艾伯維公司深信免疫學的整體護理。我們很榮幸支持學生在追求學術之旅的同時,努力擺脫免疫介導條件的限制。」
AbbVie awarded scholarships to 45 recipients split equally among dermatology, gastroenterology and rheumatology therapeutic areas. Qualified applicants were selected based on academic excellence, community leadership, essay submission and recommendation letters. By investing in their education, AbbVie intends to promote resilience and inspire hope for a future beyond their disease.
艾伯維公司授予45名學生獎學金,其中皮膚科學、胃腸病學和風溼病學領域各佔相同比例。通過投資他們的教育,艾伯維公司希望促進學生的堅韌和激發對超越疾病的未來的希望。
"Receiving the AbbVie Immunology Scholarship is more than just financial support; it is a profound validation of my dedication to achieving my personal and professional goals despite the daily battle with an inflammatory disease," said LaWanda McCraney, 2024-2025 scholarship recipient and PhD candidate at Adler University. "This scholarship is a testament to the potential impact of my work and the importance of perseverance in the face of challenges."
「獲得艾伯維免疫學獎學金不僅僅是經濟支持,更是對我在與炎症性疾病的日常鬥爭中堅持追求個人和職業目標的堅定肯定。」2024-2025年獎學金獲得者,Adler大學的博士候選人LaWanda McCraney表示,「這個獎學金證明了我的工作潛力以及面對挑戰時毅力的重要性。」
Students living with immune-mediated conditions across dermatology, gastroenterology and rheumatology seeking an associate, bachelor's, master's or doctorate degree are eligible to apply for the AbbVie Immunology Scholarship. Those interested in applying for the 2025-2026 scholarship period, can sign up here to be notified when the application period opens.
對於在皮膚病學、胃腸病學和風溼病學領域患有免疫介導性疾病並尋求學士、碩士或博士學位的學生,都有資格申請艾伯維免疫學獎學金。有意申請2025-2026年獎學金的人可以在這裏註冊,以便在申請期開啓時收到通知。
Interested students can explore eligibility criteria and apply on the newly relaunched website, .
有興趣的學生可以在重新啓動的網站上了解符合條件的要求並進行申請。
About the AbbVie Immunology Scholarship
關於艾伯維免疫學獎學金
The AbbVie Immunology Scholarship provides financial support to exceptional students living with inflammatory diseases and pursuing higher education in the United States. Through this scholarship, AbbVie's passion for patient care is extended to empower students as they pursue a degree and a life not defined by their disease. It is not necessary for scholarship applicants to have taken, currently take, or intend to take in the future, any medicine or product marketed by AbbVie, and this is not a consideration in the selection criteria. Visit to learn more.
艾伯維免疫學獎學金爲在美國追求高等教育的患有炎症性疾病的優秀學生提供經濟支持。通過這個獎學金,艾伯維將患者護理的熱情延伸到了賦予學生追求學位和不被疾病定義的生活的能力上。對於獎學金申請者來說,無需服用、當前服用或將來打算服用任何艾伯維推出的藥物或產品,這不是選擇標準。請訪問www.abbvieimmunologyscholarship.com了解更多信息。
About AbbVie
關於艾伯維公司
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
AbbVie的使命是發現和提供創新藥物和解決方案,解決當今嚴重的健康問題並應對未來的醫療挑戰。我們致力於在多個關鍵治療領域 - 免疫治療,腫瘤學,神經科學和眼科領域以及Allergan Aesthetics產品和服務方面產生顯着影響。有關AbbVie的更多信息,請訪問我們的網站。關注LinkedIn,Facebook,Instagram,X (formerly Twitter)和YouTube上的@abbvie。
Forward-Looking Statements
前瞻性聲明
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
本新聞公告中的某些聲明是前瞻性聲明,或可能被視爲依據1995年《私人證券訴訟改革法》(Private Securities Litigation Reform Act of 1995)而作出的前瞻性聲明。相信,「期望」,「預計」,「預測」和類似表述和使用將來時態或條件語態的動詞,通常用來表示前瞻性聲明。艾伯維提醒,這些前瞻性聲明受到風險和不確定性的影響,這可能會導致實際結果與前瞻性聲明中表達或暗示的結果不同。這樣的風險和不確定性包括,但不限於,知識產權的挑戰,來自其他產品的競爭,研究和開發過程中的困難,不利的訴訟或政府行動,以及適用於我們行業的法律和法規的變化。有關可能影響艾伯維運營的經濟,競爭,政府,技術和其他因素的其他信息,請參見艾伯維的2023年10-K年度報告的1A項「風險因素」,該報告已向證券交易委員會提交,並經由其後續的季度報告10-Q進行了更新。除法律規定外,艾伯維無需且特此拒絕公開披露任何對前瞻性聲明的修訂,這是因爲隨後發生的事件或發展。
References
參考
- Maslow, G. R., Haydon, A., McRee, A.-L., Ford, C. A., & Halpern, C. T. (2011). "Growing Up With a Chronic Illness: Social Success, Educational/Vocational Distress". Journal of Adolescent Health, 49(2), 206–212.
- Maslow, G. R., Haydon, A., McRee, A.-L., Ford, C. A., & Halpern, C. t. (2011).《成長中的慢性疾病:社交成功,教育/職業困擾》。《青少年健康雜誌》,49(2),206–212。
US-IMM-240094
US-IMm-240094
SOURCE AbbVie
資料來源:艾伯維公司